RecruitingNot ApplicableNCT07009886
Development of an Educational Patient Decision Aid (Treatments in Advanced Cancer - Decision Aid, TA-DA) to Promote Shared Decision Making for Third-line or Beyond Palliative Systemic Therapy
Sponsor
M.D. Anderson Cancer Center
Enrollment
155 participants
Start Date
Jul 10, 2025
Study Type
INTERVENTIONAL
Conditions
Summary
To develop an educational patient decision aid for advanced cancer patients to prepare them to have conversations with their clinicians about treatment options (Treatments in Advanced cancer - Decision Aid, TA-DA).
Eligibility
Min Age: 18 Years
Inclusion Criteria18
- Clinicians (Part I/II/III):
- MD Anderson medical oncologists and APPs who provide care to patients with advanced cancer
- Patients (Part I/II/III):
- Age 18 or over
- Diagnosis of advanced cancer (i.e., metastatic, relapsed, and/or incurable disease as defined by the treating oncologist) who has received at least 2 lines of palliative systemic therapy*
- Patient-rated ECOG performance status of 1-3 for Part I/II and 2-3 for Part III
- Able to make treatment decisions based on the clinical judgement of the oncology team
- English speaking
- patient has started, is receiving, and/or has completed second-line palliative systemic therapy or beyond
- Caregivers (Part I/II/III):
- Age 18 or older
- Currently a primary caregiver to a patient who satisfies the patient eligibility criteria listed above
- For the study purposes, a primary caregiver is defined as:
- someone who provides physical, emotional, decisional and/or logistical assistance to the patient regularly (e.g. daily, weekly);
- can be a family member, friend, or other individual in a close relationship with the patient;
- must be identified by the patient and self-identify as the primary person providing caregiving support to the patient
- Able to provide informed consent and participate in the study
- English speaking
Exclusion Criteria3
- Any patient who meets any of the following criteria will be excluded from participation in this study:
- (Part I/II/III): Diagnosis of cognitive impairment or dementia requiring a surrogate decision maker as determined by the clinical team
- (Part III only): Participants in Part I and II
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
OTHERCommunication
Participants meet with clinician
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT07009886
Related Trials
BOLSTER: Learning New Skills to Thrive
NCT069368782 locations
A Study of JZP815 Oral Capsules in Adult Participants With Advanced or Metastatic Solid Tumors Harboring Mitogen Activated Protein Kinase (MAPK) Pathway Alterations to Investigate the Safety, Dosing, and Antitumor Activity of JZP815
NCT0555704515 locations
A Study of IMC-002 in Patients With Advanced Cancer Failed to Standard Therapy
NCT052763103 locations
Toripalimab(JS001) as Monotherapy in Participants With POLE or POLD-1 Mutated and Non-MSI-H Advanced Solid Tumors
NCT038103394 locations
Combination of Immune Checkpoint in Locally Advanced or Metastatic MSI/dMMR Esogastric Adenocarcinomas
NCT063461976 locations